Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1434-1444

  Vantler, Marius ^a,b   Jesus, Joana ^a,b   Leppänen, Olli ^c   Scherner, Maximilian ^b   Berghausen, Eva Maria ^a,b   Mustafov, Lenard ^a,b   Chen, Xin ^a,b   Kramer, Tilmann ^a,b   Zierden, Mario ^a,b   Gerhardt, Maximilian ^a   Ten Freyhaus, Henrik ^a   Blaschke, Florian ^d   Sterner Kock, Anja ^b   Baldus, Stephan ^a   Zhao, Jean J ^e   Rosenkranz, Stephan ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

neointima; p110; phosphatidylinositol 3 kinase (PI3K); tyrosine kinase; vascular remodeling; vascular smooth muscle cells

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; CLASS IA PHOSPHATIDYLINOSITOL 3 KINASE ISOFORM P110ALPHA; CLASS IA PHOSPHATIDYLINOSITOL 3 KINASE ISOFORM P110BETA; CLASS IA PHOSPHATIDYLINOSITOL 3 KINASE ISOFORM P110DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK 75; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TGX 221; UNCLASSIFIED DRUG; ISOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL BALLOON CATHETER INJURY; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MOUSE MODEL; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR REMODELING; WESTERN BLOTTING; ANIMAL; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PROTEIN ISOFORMS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 84933053433     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304887     Document Type: Article

References (41)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
2. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190:300-309.
3. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058. doi: 10.1161/CIRCULATIONAHA.106.675934.
4. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res. 2013;99:353-363. doi: 10.1093/cvr/cvt115.
5. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004-2013. doi: 10.1056/NEJMra1216063.
6. Isenovi? ER, Kedees MH, Tepavcevi? S, Milosavljevi? T, Kori?anac G, Trpkovi? A, Marche P. Role of PI3K/AKT, cPLA2 and ERK1/2 signaling pathways in insulin regulation of vascular smooth muscle cells proliferation. Cardiovasc Hematol Disord Drug Targets. 2009;9:172-180.
7. Iglesias PA. Spatial regulation of PI3K signaling during chemotaxis. Wiley Interdiscip Rev Syst Biol Med. 2009;1:247-253. doi: 10.1002/wsbm.13.
8. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415:333-344. doi: 10.1042/BJ20081056.
9. Caglayan E, Vantler M, Leppänen O, Gerhardt F, Mustafov L, Ten Freyhaus H, Kappert K, Odenthal M, Zimmermann WH, Tallquist MD, Rosenkranz S. Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase C? 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo. J Am Coll Cardiol. 2011;57:2527-2538. doi: 10.1016/j.jacc.2011.02.037.
10. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329-341. doi: 10.1038/nrm2882.
11. Stephens L, Hawkins P. Signalling via class IA PI3Ks. Adv Enzyme Regul. 2011;51:27-36. doi: 10.1016/j.advenzreg.2010.09.007.
12. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13:195-203. doi: 10.1038/nrm3290.
13. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci. 2009;34:115-127. doi: 10.1016/j.tibs.2009.01.003.
14. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30:194-204. doi: 10.1016/j.tibs.2005.02.008.
15. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627-644. doi: 10.1038/nrd2926.
16. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010;70:2146-2157. doi: 10.1158/0008-5472.CAN-09-4355.
17. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res. 2009;82:261-271. doi: 10.1093/cvr/cvn325.
18. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A. 2008;105:8292-8297. doi: 10.1073/pnas.0707761105.
19. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274:10963-10968.
20. Li L, Miano JM, Cserjesi P, Olson EN. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circ Res. 1996;78:188-195.
21. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, Hammer RE, Herz J, Kuhn M. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A. 2002;99:7142-7147. doi: 10.1073/pnas.102650499.
22. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, Higashi K, Volinia S, Downward J, Waterfield MD. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A. 1997;94:4330-4335.
23. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008;454:776-779. doi: 10.1038/nature07091.
24. Pimentel B, Rodríguez-Borlado L, Hernández C, Carrera AC. A Role for phosphoinositide 3-kinase in the control of cell division and survival during retinal development. Dev Biol. 2002;247:295-306.
25. Sheng H, Shao J, Townsend CM Jr, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut. 2003;52:1472-1478.
26. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18:2262-2271. doi: 10.1016/j.cellsig.2006.05.019.
27. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008;453:662-666. doi: 10.1038/nature06892.
28. Holy EW, Jakob P, Eickner T, Camici GG, Beer JH, Akhmedov A, Sternberg K, Schmitz KP, Lüscher TF, Tanner FC. PI3K/p110? inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design. Eur Heart J. 2014;35:808-820. doi: 10.1093/eurheartj/eht496.
29. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005;24:1477-1480. doi: 10.1038/sj.onc.1208304.
30. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011;10:558-565. doi: 10.1158/1535-7163.MCT-10-0994.
31. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:121-130. doi: 10.1517/14728222.2011.644788.
32. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747. doi: 10.1016/j.cell.2006.03.035.
33. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007;15:5837-5844. doi: 10.1016/j.bmc.2007.05.070.
34. Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, Styp-Rekowska B, Djonov V, von Bueren AO, Frei K, Arcaro A. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One. 2014;9:e94132. doi: 10.1371/journal.pone.0094132.
35. Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011;4:104-111. doi: 10.1161/CIRCINTERVENTIONS.110.957332.
36. Kim EK, Tucker DF, Yun SJ, Do KH, Kim MS, Kim JH, Kim CD, Birnbaum MJ, Bae SS. Linker region of Akt1/protein kinase Balpha mediates platelet-derived growth factor-induced translocation and cell migration. Cell Signal. 2008;20:2030-2037. doi: 10.1016/j. cellsig.2008.07.012.
37. Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem. 2011;112:1572-1584. doi: 10.1002/jcb.23069.
38. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9:690-701. doi: 10.1038/nrm2476.
39. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-3511.
40. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000;14:3102-3114.
41. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal. 2008;1:ra3. doi: 10.1126/scisignal.1161577.